Tags : Orphan Drug Designations

Galecto’s GB0139 Receives the US FDA’s and EMA’s Orphan Drug

Shots: The US FDA and EMA has received ODD to Galecto’s GB0139 for the treatment of IPF. GB0139 showed significant reduction of YKL-40 biomarker in fibrosis, inflammation, tissue remodeling diseases in its first clinical study after 14 days of treatment The EMA cited GB0139’s clinically relevant biomarker data in IPF patients which provides financial incentives, […]Read More